Business

Suddenly, the Bristol-Celgene deal is looking shaky. What's next?




W happened to Celgene (CELG) at the proposed $ 74 billion acquisition by Bristol-Myers Squibb (BMY) dies

"That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on his board are doing everything they can to prevent the deal from unraveling, ”said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED



Source link

Back to top button